Location of Repository

Metronomic Cyclophosphamide and Methotrexate Chemotherapy Combined with 1E10 Anti-Idiotype Vaccine in Metastatic Breast Cancer

By Jorge L. Soriano, Noyde Batista, Eduardo Santiesteban, Mayté Lima, Joaquín González, Robin García, Yohanka Zarza, María V. López, Myriam Rodríguez, Jorge L. Loys, Narciso Montejo, Frank Aguirre, Amparo Macías and Ana M. Vázquez


The use of low doses of cytotoxic agents continuously for prolonged periods is an alternative for the treatment of patients with metastatic breast cancer who have developed resistance to conventional chemotherapy. The combination of metronomic chemotherapy with therapeutic vaccines might increase the efficacy of the treatment. Twenty one patients with metastatic breast cancer in progression and a Karnosky index ≥60%, were treated with metronomic chemotherapy (50 mg of cyclophospamide orally daily and 2.5 mg of methotrexate orally bi-daily), in combination with five bi-weekly subcutaneous injections of 1 mg of aluminum hydroxide-precipitated 1E10 anti-idiotype MAb (1E10-Alum), followed by reimmunizations every 28 days. Five patients achieved objective response, eight showed stable disease and eight had disease progression. Median time to progression was 9,8 months, while median overall survival time was 12,93 months. The median duration of the response (CR+PR+SD) was 18,43 months (12,20–24,10 months), being higher than 12 months in 76,9% of the patients. Overall toxicity was generally mild. Metronomic chemotherapy combined with 1E10-Alum vaccine immunotherapy might be a useful therapeutic option for the treatment of metastatic breast cancer due to its potential impact on survival and patient quality of live, low toxicity and advantages of the administration

Topics: Clinical Study
Publisher: SAGE-Hindawi Access to Research
OAI identifier: oai:pubmedcentral.nih.gov:3262579
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles



    1. (2004). A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens,”
    2. (2005). Angiogenesis of breast cancer,”
    3. (2002). Breast cancer: metastatic,”
    4. (2006). Cellular and humoral immune response to N-glycolyl-GM3 elicited by prolonged immunotherapy with an anti-idiotypic vaccine in high-risk and metastatic breast cancer patients,”
    5. (1999). Chemotherapy agents as antiangiogenic therapy,”
    6. (2010). Combined therapeutic effect of a monoclonal anti-idiotype tumor vaccine against NeuGc-containinggangliosideswithchemotherapyinabreast carcinoma model,”
    7. (2007). De La Torre et al., “Active immunotherapy with 1E10 anti-idiotype vaccine in patients with small cell lung cancer: report of a phase I trial,”
    8. (2004). Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model,”
    9. (2001). Efficacy and mechanisms of action of rmB7.2-Ig as an antitumor agent in combination with adriamycin and cytoxan chemotherapy,”
    10. (2006). Evaluating strategies to enhance the anti-tumor immune response to a carbohydrate mimetic peptide vaccine,”
    11. (1995). Generation of a murine monoclonal antibody specific for N- glycolylneuraminic acid-containing gangliosides that also recognizes sulfated glycolipids,”
    12. (2009). Gonz´ alez et al., “Quimioterapia metron´ omica con ciclofosfamida y metotrexate en pacientes con c´ ancer de mama metast´ asico en progresi´
    13. (2002). Hern´ andez et al., “An anti-idiotype vaccine elicits a specific response to N-glycolyl sialic acid residues of glycoconjugates in melanoma patients,”
    14. (2000). Hern´ andez et al., “Antitumor properties of an anti-idiotypic monoclonal antibody in relation to N-glycolyl-containing gangliosides,”
    15. (1998). Hern´ andez et al., “Syngeneic anti-idiotypic monoclonal antibodies to an anti-NeuGccontaining ganglioside monoclonal antibody,”
    16. (2003). Immune responses in breast cancer patients immunized with an anti-idiotype antibody mimicking NeuGc-containing gangliosides,”
    17. (2005). Immunotherapy and chemotherapy—apracticalpartnership,”Nature
    18. (1999). Interferon-α-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule,”
    19. (2000). Less is, more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice,”
    20. (2006). Low-dose metronomic daily cyclophosphamide and weekly tirapazamine: a well-tolerated combination regimen with enhanced efficacy that exploits tumor hypoxia,”
    21. (2007). Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients,”
    22. (2003). Minimizing longterm tumor burden: the logic for metronomic chemotherapeutic dosing and its antiangiogenic basis,”
    23. (1996). New perspectives in clinical oncology from angiogenesis research,”
    24. (2001). Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches,” Cancer and Metastasis Reviews,
    25. (2006). Prolonged clinical benefit with metronomic chemotherapy
    26. (2000). r o w d e r ,C .E .B u t t e r fi e l d ,B .M .K r ¨ aling et al., “Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer,”
    27. (1999). Results and long term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing6
    28. (2004). Soubasakos et al., “Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide mediated endothelial cell apoptosis and tumor growth suppression,”
    29. (2004). The anti-angiogenic basis of metronomic chemotherapy,”

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.